PCSK9 inhibitors in the prevention of cardiovascular disease

Reducing plasma levels of low-density lipoprotein cholesterol (LDL-C) remains the cornerstone in the primary and secondary prevention of cardiovascular disease. However, lack of efficacy and adverse effects mean that a substantial proportion of patients fail to achieve acceptable LDL-C levels with c...

Descripción completa

Detalles Bibliográficos
Autores principales: Latimer, James, Batty, Jonathan A., Neely, R. Dermot G., Kunadian, Vijay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010583/
https://www.ncbi.nlm.nih.gov/pubmed/27095708
http://dx.doi.org/10.1007/s11239-016-1364-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5010583/
https://www.ncbi.nlm.nih.gov/pubmed/27095708
http://dx.doi.org/10.1007/s11239-016-1364-1

Ejemplares similares